RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
Investigational drugs opaganib and RHB-107 (upamostat) demonstrate distinct synergistic effect when combined individually with remdesivir, significantly improving potency while maintaining cell viability, in a new U.S. Army-funded and conducted in vitro Ebola virus study
Related news for (RDHL)
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/21/25 01:00 PM
- Top Biotech Movers: Transformative Breakthroughs Fuel Investor Interest Across Neurology, Autoimmunity, and Advanced Materials
- Breaking News: MoBot’s Latest Update as of 05/13/25 08:00 AM
- 24/7 Market News Snapshot 13 May, 2025 – Redhill Biopharma Ltd. (NASDAQ:RDHL)
- Today’s Top Performers: MoBot’s Market Review 04/16/25 08:00 AM